Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Kerr

Sports Medicine Traverse City, MI Medical Doctor

NPI 1407940190 CMS profile 200042

4045 W Royal Dr, Traverse City, MI 49684

Open in the dashboard

General payments

$3,201

30 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Kerr of Traverse City, MI is reported in the CMS Open Payments database as having received $3,201 across 30 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 34th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $75 2
2024 General $410 5
2023 General $27 2
2022 General $27 3
2020 General $1,532 16
2019 General $1,130 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Kerr
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Brian Kerr were reported at $75. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Brian Kerr Sports Medicine median Middle half National median
2019 $1,130 $1,176 $199–$4,249 $163
2020 $1,532 $708 $96–$2,890 $114
2021 $0 $1,213 $152–$3,994 $132
2022 $27 $1,230 $159–$3,998 $149
2023 $27 $584 $146–$2,836 $160
2024 $410 $628 $163–$3,168 $164
2025 $75 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $2,182 17 payments
  2. Smith+Nephew, Inc. $699 2 payments
  3. Lightbody Medical Technologies Inc $130 1 payment
  4. Stryker Corporation $51 1 payment
  5. Linvatec Corporation $37 2 payments
  6. Embody, Inc. $35 4 payments
  7. Zimmer Biomet Holdings, Inc. $31 1 payment
  8. Radius Health, Inc. $24 1 payment
  9. Sunovion Pharmaceuticals Inc. $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $2,141 6 payments
  2. Food and Beverage $1,060 24 payments
Products named General payments · program years 2019–2025
  1. ACCUPASS DIRECT Crescent XL $668 1 payment
  2. Suturefix $668 1 payment
  3. Q-Fix $668 1 payment
  4. Arthrex Capital Consumables - Consumables - Legacy Synergy Resection System - H Blades & Burrs $131 1 payment
  5. Arthrex Biologics - Consumables - Bone Repair - Cellular Bone Grafting Kit $99 1 payment
  6. SYSTEM 9 CD NXT $51 1 payment
  7. Gel-One Cross-linked Hyaluronate $31 1 payment
  8. Hip Positioning System $31 1 payment
  9. HEALICOIL PK Shoulder $31 1 payment
  10. Q-FIX Shoulder $31 1 payment
  11. Other $172 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

353

Median for Orthopedic Surgery: 203

Drug cost

$1,388

Median for Orthopedic Surgery: $1,433

Branded share of claims

28.9%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 83 $709
Acetaminophen-Codeine Acetaminophen With Codeine Brand 19 $160
Ondansetron Hcl Generic 102 $156
Omeprazole Generic 41 $151
Naproxen Generic 59 $147
Tramadol Hcl Generic 16 $40
Meloxicam Generic 33 $26

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$69,051

Of which drugs: $800

Medicare patients

166

Average age 72

Services billed

3,416

77 women, 89 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 61%
Depression 17%
Ischemic heart disease 15%
Diabetes 14%
Atrial fibrillation 13%
Chronic kidney disease 11%
Cancer 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 25 2,600 $250
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 20 216 $162
Injection, methylprednisolone acetate, 40 mg J1030 Office 14 33 $96

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

30 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record